Bayesian estimation of individual parameters in an HIV dynamic model using long-term viral load data

Deterministic and Stochastic Models of AIDS Epidemics and HIV Infections with Intervention

Volumn , Issue , 2005, Pages 361-383

  Huang, Yangxin ^a   Wu, Hulin ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Hierarchical Bayesian models; HIV dynamics; MCMC; Parameter estimation; PK PD modeling; Treatment efficacy

Indexed keywords

EID: 84967355267     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9789812569264_0015     Document Type: Chapter

References (47)

1. Bennett JE, Racine-Poon A and Wakefield JC (1996) Markov chain Monte Carlo for nonlinear hierarchical models, in Gilks WR, Richardson S and Spiegelhalter DJ (eds), Markov Chain Monte Carlo in Practice, pp. 339-357, Chapman & Hall, London.
2. Besch CL (1995) Compliance in clinical trials. AIDS 9: 1-10.
3. Bonhoeffer S, Lipsitch M and Levin BR (1997) Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci USA 94: 12106-12111.
4. Callaway DS and Perelson AS (2002) HIV-1 infection and low steady state viral loads. Bull Math Biol 64: 29-64.
5. Carlin BP and Louis TA (1996) Bayes and Empirical Bayes Methods for Data Analysis. Chapman & Hall, London.
6. Chib S and Greenberg E (1995) Understanding the Metropolis-Hastings algorithm. The American Statistician 49: 327-335.
7. Davidian M and Giltinan DM (1995) Nonlinear Models for Repeated Measurement Data. Chapman & Hall, London.
8. Ding AA and Wu H (1999) Relationships between antiviral treatment effects and biphasic viral decay rates in modeling HIV dynamics. Math Biosci 160: 63-82.
9. Ding AA and Wu H (2000) A comparison study of models and fitting procedures for biphasic viral decay rates in viral dynamic models. Biometrics 56: 16-23.
10. Ding AA and Wu H (2001) Assessing antiviral potency of anti-HIV therapies in vivo by comparing viral decay rates in viral dynamic models. Biostatistics 2: 13-29.
11. Fitzgerald AP, DeGruttola VG and Vaida F (2002) Modelling HIV viral rebound using non-linear mixed effects models. Stat Med 21: 2093-2108.
12. Frost SDW (2001) Bayesian modeling of viral dynamics and evolution. AIDS Cyber J 4(2).
13. Gamerman D (1997) Markov Chain Monte Carlo: Stochastic Simulation for Bayesian Inference. Chapman & Hall, London.
14. Gelfand AE et al. (1990) Illustration of Bayesian inference in normal data models using Gibbs sampling. J Amer Stat Assoc 85: 972-985.
15. Gelfand AE and Smith AFM (1990) Sampling-based approaches to calculating marginal densities. J Amer Stat Assoc 85: 398-409.
16. Gelman A, Bois F and Jiang J (1996) Physiological pharmacokinetic analysis using population modeling and informative prior distributions. J Amer Stat Assoc 91: 1400-1412.
17. Han C, Chaloner K and Perelson AS (2002) Bayesian analysis of a population HIV dynamic model. Case Studies in Bayesian Statistics, Vol. 6. Springer-Verlag, New York.
18. Ho DD, Neumann AU, Perelson AS et al. (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373: 123-126.
19. Hsu A, Isaacson J et al. (2000) Trough concentrations-ÆC⅛o relationship as a predictor of viral response for ABT-378/ritonavir in treatment-experienced patients, in 40th Interscience Conference on Antimicrobial Agents and, Chemotherapy. San Francisco, CA, Poster session 171.
20. Huang Y, Rosenkranz SL and Wu H (2003) Modeling HIV dynamics and antiviral responses with consideration of time-varying drug exposures, sensitivities and adherence. Math Biosci 184: 165-186.
21. Huang Y and Wu H (2004a) A Bayesian approach for estimating antiviral efficacy in HIV dynamic models. J App Stat (submitted).
22. Huang Y and Wu H (2004b) Mechanistic PK/PD modeling of antiretroviral therapies in AIDS clinical trials, in: Biomedical Simulations Resource PK/PD. Kluwer Academic Publishers, New York.
23. Ickovics JR and Meisler AW (1997) Adherence in AIDS clinical trial: a framework for clinical research and clinical care. J Clin Epidemiol 50: 385-391.
24. Kempf DJ, Hsu A, Jiang P et al. (2001) Response to ritonavir intensification in indinavir recipients is highly correlated with virtual inhibitory quotient, in 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, Abstract 523.
25. Klenernam P, Phillips RE et al. (1996) Cytotoxic T lymphocytes and viral turnover in HIV type 1 infection. Proc Natl Acad Sci USA 93: 15323-15328.
26. Lunn DJ, Best N et al. (2002) Bayesian analysis of population PK/PD models: general concepts and software. J Pharmacokinet Pharmacodyn 29: 271-307.
27. Markowitz M, Louie M et al. (2003) A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol 77: 5037-5038.
28. Molla A et al. (1996) Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 2: 760-766.
29. Nelson PW and Perelson AS (2002) Mathematical analysis of delay differential equation models of HIV-1 infection. Math Biosci 179: 73-94.
30. Nowak MA, Bonhoeffer S et al. (1995) HIV results in the frame. Nature 375: 193.
31. Nowak MA, Bonhoeffer S, Shaw GM and May RM (1997) Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. J Theor Biol 184: 203-217.
32. Nowak MA and May RM (2000) Virus Dynamics: Mathematical Principles of Immunology and Virology. Oxford University Press, Oxford.
33. + T cells. Math Biosci 114: 81-125.
34. Perelson AS, Neumann AU, Markowitz M, Leonard JM and Ho DD (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271: 1582-1586.
35. Perelson AS, Essunger P et al. (1997) Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387: 188-191.
36. Perelson AS and Nelson PW (1999) Mathematical analysis of HIV-1 dynamics in vivo. SIAM Rev 41: 3-44.
37. Putter H, Heisterkamp SH, Lange JMA and De Wolf F (2002) A Bayesian approach to parameter estimation in HIV dynamical models. Stat Med 21: 2199-2214.
38. Sheiner LB (1985) Modeling pharmacodynamics: parametric and nonpara- metric approaches, in Rowland M et al. (eds) Variability in Drug Therapy: Description, Estimation, and Control, pp. 139-152, Raven Press, New York.
39. Smith AFM and Roberts GO (1993) Bayesian computation via the Gibbs sampler and related Markov chain Monte Carlo methods. J Roy Stat Soc B 55: 3-23.
40. Stafford MA et al. (2000) Modeling plasma virus concentration during primary HIV infection. J Theor Biol 203: 285-301.
41. Wahl LM and Nowak MA (2000) Adherence and resistance: predictions for therapy outcome. Proc Roy Soc Biol 267: 835-843.
42. Wainberg MA et al. (1996) Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substition in 3TC-resistant HIV-1 reverse transcriptase. AIDS 10(suppl): S3-S10.
43. Wakefield JC, Smith AFM, Racine-Poon A and Gelfand AE (1994) Bayesian analysis of linear and non-linear population models using the Gibbs sampler. App Stat 43: 201-221.
44. Wakefield JC (1996) The Bayesian approach to population Pharmacokinetic models. J Amer Stat Assoc 91: 61-76.
45. Wei X, Ghosh SK et al. (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373: 117-122.
46. Wu H, Ding AA and de Gruttola V (1998) Estimation of HIV dynamic parameters. Stat Med 17: 2463-2485.
47. Wu H and Ding AA (1999) Population HIV-1 dynamics in vivo: applicable models and inferential tools for virological data from AIDS clinical trials. Biometrics 55: 410-418.